The past year has seen the publication of a number of landmark papers (with accompanying editorials) on interventions in acute coronary syndromes (ACS) 1, 2, 3, 4, 5, 6, 7 and the relationship of these interventions to cardiac markers. 8, 9 Two consensus documents on the use of cardiac markers for the investigation of patients with ACS have also been produced, one by the National Academy of Clinical Bi ochemi sts (NACB) 10 and one by the International Federation of Clinical Chemists (IFCC). 11 Both consensus documents are consistent (as they are related) although one (NACB) has a t ransat lanti c and the ot her (IFCC) a more cosmopolitan flavour. Both recommend an overall strategy for cardiac markers but questions remain. Can these recommendations be translated into UK clinical practice? Have developments occurred since the original documents were written that make them more or less relevant? Both documents suggest standards about choice of markers, sample timing strategies and targets for turn-around time (TAT).
The first and most important feature is the use of the term 'acute coronary syndromes'. It is no longer clinical practice to divide patients into acute myocardial infarction (AMI) or not. Management of patients with suspected acute ischaemic heart disease (IHD) no longer distinguishes between non-Q-wave AMI and unst abl e angina. T he concept of the dynamic progression of an active unstable plaque as the genesis of both unstable angina and myocardial infarction is well accepted. This in turn means that there will be a complete spectrum of coronary artery diseases determined by total plaque burden and plaque stability with the presentation dependant on plaque activity, plaque location and degree of stenosis.
A wide range of diagnostic testing strategies is still in use in the UK (Owen A, personal communication). Nearly all laboratories measure creatine kinase (CK) but the use of CK-MB isoenzyme measurement is limited, despite the evidence for superior cli nical and diagnost ic sensi-tivity. 12, 13, 14, 15, 16 The number of laboratories offering measurement of CK-MB mass, the method of choice, 17 is low. Similarly, there is a variety of sampling strategies, with many laboratories recommending daily measurement of cardiac enzymes. Two factors seem to have produced the present situation. Firstly, the cost and convenience of CK-MB measurement. Only recently have methods for CK-MB mass become available that do not require a dedicated analyser but can be run on a routine automated immunoassay platform. This has been accompanied by a fall in test cost. Secondly, there has been a lack of perceived clinical value of newer tests and of the benefit of more rapid diagnostic strategies. How far do the publications mentioned above address these issues and how far away is the UK from an acceptable st andard of clinical practice?
WHICH MARKER FOR THE DETECTION OF MYOCARDIAL INJURY?
There is a clear consensus that cardiac troponin (cTn) measurement, either cardiac troponin T (cTnT) or cardiac troponin I (cTnI) is the best marker for the definitive detection of myocardial damage and will replace CK-MB. Meta-analysis of published studies has shown that detection of cTnT and cTnI in the serum of patients with unstable angina predicts a high risk of a subsequent cardiac event. 18 As a late marker for AMI, cTn has no equal. Some laboratories retain measurement of lactate dehydrogenase (LD) for late diagnosis. This should no longer be part of the cardiac enzyme profile offered by any hospital. The lack of cardiac specificity and poor time window means that, at the very least, LD should be replaced by a measurement of either cTnT or cTnI.
The definition of my ocardial infarction is currently undergoing re-evaluation. Historically, the concept of the non-Q AMI originated when biochemical detection of myocardial necrosis demonstrated t hat AMI coul d occur without classical electrocardiogram (ECG) changes. Since then, we have seen progressive evolution of markers with the advent of LD isoenzymes, CK, then CK-MB measurement (initially as activity and now as mass measurement). The introduction of progressively more sensitive tests has led to a progressive 'creep' in diagnostic categorisation. The use of cTn as the 'gold standard' for infarction therefore represents no more than the continuation of this trend. The spectrum of coronary artery disease plus the high sensitivity of cTnT and cTnI measurements explains the detection of myocardial damage in patients who fail to meet the 'classic' criteria for AMI. More importantly, measurement of cTnT and cTnI can be related to outcome. Oneyear mortality in AMI patients who receive thrombolysis is typically 6%. The 1-year mortality of 'conventional' non-Q AMI and cTnT or cTnI positive unstable angina pectoris (UAP) are both 15-20%. Pragmatically, the use of a cut-off for cTn corresponding to the 99th centile of a reference population as the diagnostic criterion for AMI will effectively increase the numbers of non-Q AMI patients presenting without ST-segment elevation, from 4% to 13%.
Cardiac troponin measurement is now perceived by clinical cardiologists as one of the tools for management of ACS patients. The use of routine measurement of cTn is now being described in the handbooks i ssued to j unior doctors and i n documents recommending investigation and treatment strategies. 19 The main barrier to the introduction of cardiac troponin measurement into routine clinical practice in the UK has not been diagnostic sensitivity and specificity but rather cost. Those hospitals that have introduced cardiac troponin testing have been able to demonstrate cost reduction, either direct reduction in laboratory testing costs (Manning E, personnel communication) or by improvement in clinical process. 20 Certainly, for those hospitals offering CK-MB mass, direct substitution of troponin measurement offers an immediate cost saving.
Both publications recommend the use of two markers. An optimal combination would be the use of a short time window marker combined with a cardiac troponin. This would enable infarct timing as well as the detection of reperfusion and reinfarction. The choice of short time window of marker remains a matter of debate. Myoglobin measurement can now be performed in real time and it is time to reappraise the role of this marker for early detection of AMI. The alternative to myoglobin would be a measurement of CK or CK-MB. Clearly, CK-MB mass is a superior test and is the only test which meets proposed analytical goals. However, measurement of CK has the merit of simplicity and cost-efficiency. When delta values are used rather than comp arison with conventional reference values, CK is as sensitive as CK-MB mass. 16 
WHEN SHOULD SAMPLES BE TAKEN?
The sampling strategies used for investigation of patients with suspected acute coronary syndrome must be tailored to local circumstances, the practicalities of delivering a laboratory service and the way that the test results will be used. It is here that the two documents diverge. The recommendations in both are for the use of more frequent sampling strategies, based on the concept of rapid diagnosis for risk stratification.
The NACB policy advocates an aggressive strategy but this must be seen in the context of the rapid development in the US of chest pain units (CPU) for early aggressive investigation of ACS 21 . The IFCC document is more conservative. For UK clinical practice, biochemical markers need to be integrated into an overall clinical decisionmaking strategy, but this must be backed by an infrastructure which will deliver appropriate pathways of care. Current clinical practice in the UK is based on a strategy of initially dividing patients into those at high and low risk of cardiac events on the basis of clinical and ECG findings followed by biochemical testing. This differs from US and European practice, not in the recognition of IHD but in the availability of clinical resources for admission and investigation. In the UK, we admit only patients with AMI and Brunwald IIIb unstable angina; everyone else is managed as an outpatient. This approach causes consternation amongst US cardiologists.
Patients with ST-segment elevation at presentation require fast-track thrombolysis, infarct sizing and diagnostic confirmation. Patients judged to be at high risk of IHD require a test to rule out AMI on admission and receive subsequent investigation by stress testing, nuclear cardiography or angiography, as appropriate. The traditional approach of daily enzyme measurement can and should be replaced by a more aggressive strategy to achieve earlier diagnosis. A single cTn measurement 12-24h from admission will be sufficient, when combined with the ECG, to categorise patients into t hose wit h or wit hout myocardial damage. Pragmatically, and until clinicians are used to cTn measurement alone, this can be combined with measurement of CK on admission and in the 12-24h window. This is a minimalist strategy that ignores the additional benefit of cTn measurement on admission. 22 Patients with a low clinical risk of IHD, an atypical history and no ECG changes have a low risk of AMI and are discharged from the emergency department. The incidence of missed AMI in this group is around 6%. 23 A strategy for early exclusion of the diagnosis of AMI by the use of an earlier and more frequent sampling protocol is appropriate for this group only as part of a chest pain evaluation strategy. Patients initially assessed as being at low risk of IHD and AMI can be investigated either in the emergency department or in a chest pain evaluation area. Serial measurement of biochemical markers over a 4-6h period will successfully rule out prognostically significant myocardial damage in >95% of cases. 24, 25 It must be remembered that patients with ACS will still be missed. The prior probability of IHD is only 6% in this patient group. This will mean only 3 per 1000 cases screened will be discharged. Such patients, with an atypical history and no ECG findings, are at relatively low risk.
HOW QUICKLY SHOULD WE RETURN RESULTS?
The target for TAT has been suggested as 60 min, with plasma as the preferred sample matrix. The supplementary recommendation accompanying this is that point of care testing (POCT) should be considered if central laboratory testing (CLT) cannot achieve this target. This suggestion is arbitrary rather than evidence-based. If the patient is going to be admitted for 2-3 days, TAT is less critical than if the patient is held in the emergency department for exclusion of AMI. The target for TAT is dependent on the use to which the information will be put. In a prospective trial of rapid diagnosis, it was found that a short TAT reduced length of stay only in patients for whom diagnosis and management decisions were dependent on marker measurement. 26 A pragmatic approach would be to say that TAT should be less than 25% of the total time frame for decision making, with the choice of POCT or CLT (or both) dependent on local circumstances. This then can be used as a framework to decide the type of service required. For in-patients where early diagnosis is planned, results must be provided in time for the clinical round. Here, a daily service providing results by 09:00 may be sufficient. In practice a twice daily may be required. This will have to be provided on a 7 day a week basis. In this case, POCT analysis performed by the laboratory may be used to supplement the main service, and add a convenient 'stat' capacity. When very rapid service is required for early discharge from the ED, the choice between POCT and CLT will be determined by the ability of the laboratory to achieve TAT targets. This will depend on local logistical arrangements. A 24 h stat service is required either by CLT, by the lab using POCT type technology or by POCT alone. Absolute recommendations on POCT vs CLT cannot be made. They are complementary technologies. The latest generation of whole blood quantitative analyzers can be used in either a CLT or POCT role and should be used in an appropriate mix according to local circumstances. 27, 28 The only time when POCT will be clearly superior is when therapeutic decisions have to be made based on the results of laboratory test results. Here, POCT will be superior, because it will be faster and the results immediately available for action. Reduction in TAT can be translated into reduction in length of stay, 29 hence improved bed availability, a pertinent issue as the demand for beds continues to rise.
DO NEW DATA ON INTERVENTION SUPPORT THE RECOMMENDATIONS?
The most recent data have shown that cardiac troponin measurement can be used to select those patients who will respond to low molecular heparin therapy 30 and glycoprotein IIb/IIIa antagonists. 8, 9 Analysis of data from the FRISC II trial has shown that early revascularization is of benefit in patients with high-risk ACS. 5 It is likely that this effect will be confined to the troponin-positive group. 31 This suggests that cTn measurement should also be performed on admission, and possibly at more frequent intervals. This will also require a more rapid turnaround time, since the decision to start or stop expensive therapeutic interventions may be made on the basis of biochemical testing.
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IS IT P OSSIBLE TO ACHIEVE THESE STANDARDS?
An appropriate clinical decision-making pathway incorporating troponin and other markers can be used to efficiently categorize patients into highand low-risk groups for appropriate management pathways and to select for interventions. In an era of evidence-based medicine, we can no longer overlook the diagnostic, prognostic and therapeutic benefi ts provided by more intensive bl ood sampling regimens and measurement of the cardiac troponins. Modern immunoassay platforms are capable of rapidly performing cTn (and other cardiac marker) measurements on a 24h basis. There are also reli able point-of-care testing systems. It is therefore possible to provide rapid, 24-h troponin measurement for integrated clinical decision-making.
We are currently far from achievi ng t hi s scenario, from both the clinical and laboratory perspectives. Clinicians must agree protocols, then abide by them. Blood samples must then be taken and sent to the laboratory. At the Mayday hospital, the use of an extended role for the coronary care unit nursing staff ensured appropriate venipuncture and adherence to protocols. The use of clinical nurse specialists may therefore be the solution. The problem for the laboratory is the funding of a modern, evidence-based, 24h diagnostic service. A shift to patient episode-based cost rather than the current rigid departmental budgetary approach will allow the process to become more transparent and reveal where the true cost pressures lie. Can the NHS then afford this evidence-based medicine? It depends on how you select the evidence.
